EMA recommends five new medicines addressing rare diseases and aggressive cancers
EU Reporter —
The European Medicines Agency (EMA) has recommended five new medicines for approval following its Committee for Medicinal Products for Human Use (CHMP) meeting in March 2026, marking another step forward in addressing unmet medical needs across oncology, rare diseases and paediatrics. Among the highlights is Adstiladrin (nadofaragene firadenovec), recommended for adults with Bacillus Calmette-Guérin (BCG)-unresponsive […]